Most Common Side Effects of Yervoy
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, causes immune-related adverse events due to its CTLA-4 blockade, which ramps up T-cell activity against tumors but can also attack healthy tissues. The most frequent side effects, seen in over 10% of patients in clinical trials, include fatigue (41-49%), diarrhea (32-39%), itching (31-37%), rash (29-45%), and nausea (26-44%). Less common but notable ones are headache (23-33%), back pain (21-24%), fever (18-29%), vomiting (17-23%), abdominal pain (16-22%), and decreased appetite (15-22%).[1][2]
Why Do These Side Effects Happen?
Yervoy boosts the immune system, leading to inflammation in organs like the gut (colitis), skin (dermatitis), liver (hepatitis), and endocrine glands (thyroiditis or hypophysitis). Enterocolitis affects up to 34% of patients, often requiring steroids or hospitalization. Skin reactions like rash or pruritus hit 40-50%, while fatigue stems from systemic inflammation.[1][3]
Severe or Immune-Related Side Effects Patients Search For
About 20-40% experience grade 3-4 (severe) events, including colitis (7-10%), hepatitis (1-4%), hypophysitis (up to 13%), pneumonitis (1-2%), and adrenal insufficiency. Rare but life-threatening cases involve Guillain-Barré syndrome or myocarditis. These often appear 2-12 weeks after starting treatment and may persist post-discontinuation.[1][2][4]
How Long Do Side Effects Last, and What If They Worsen?
Mild effects like rash or diarrhea resolve in days to weeks with supportive care. Severe immune reactions can last months, needing immunosuppressants. Patients report lingering fatigue or neuropathy. Monitor for dehydration from diarrhea or confusion from endocrinopathies; stop Yervoy if grade 3-4 occurs and consult oncology immediately.[1][3]
Side Effects in Combination Therapy (Yervoy + Opdivo)
When paired with nivolumab (Opdivo), rates climb: fatigue (over 50%), diarrhea (over 40%), rash (over 50%), and severe events like colitis (10-15%). Liver enzyme elevations hit 20-30%. Trials show higher toxicity but improved survival in melanoma and renal cell carcinoma.[2][4]
Management Tips from Prescribing Info
Dose reductions aren't standard; hold for moderate issues, discontinue for severe. Use topical steroids for skin, antidiarrheals for gut, and hormone replacement for endocrine failures. Premedication isn't routine, but prophylaxis with budesonide reduces colitis risk in some studies.[1][3]
[1]: Yervoy Prescribing Information (Bristol Myers Squibb)
[2]: FDA Label for Ipilimumab
[3]: NCCN Guidelines: Melanoma (Version 2.2024)
[4]: CheckMate Trials (NEJM)